Orthocell jumps as nerve repair tech shows hope for erectile dysfunction post-prostate surgery
Orthocell shares popped +10% as the company reported its flagship nerve repair product, Remplir, is being used by Australian urologists.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
SMJ | Ann: Removal from official list | 01/02/12 | 0 | 512 | |||
|
|||||||
SMJ | Ann: SMJHB - Suspension from official quotation | 31/01/12 | 0 | 538 | |||
|
|||||||
SMJ | Ann: Annual Report to shareholders | 22/12/11 | 0 | 445 | |||
|
|||||||
SMJ | Ann: Full Year Statutory Accounts | 21/10/10 | 0 | 744 | |||
|
|||||||
SMJ | Ann: Full Year Statutory Accounts | 25/09/09 | 0 | 437 | |||
|
|||||||
SMB +SMJ SMV | Ann: Amendments to 2008 Annual Reports. | 01/12/08 | 0 | 687 | |||
|
|||||||
SMJ | Ann: 2008 Annual Report (amended) | 01/12/08 | 0 | 449 | |||
|
See All Discussions